Diligence memo · auto-generated · as of July 3, 2026
Viamet Pharmaceuticals Inc
Viamet Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Viamet Pharmaceuticals Inc operates in Pharmaceuticals, based in MORRISVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Viamet Pharmaceuticals Inc has raised $35M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2009-06-23.
Most recent recorded round closed around 2009-06-23.
Valuation (modeled)modeled
Provath models Viamet Pharmaceuticals Inc at approximately $850M (range $52M–$3.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 76% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Glycomimetics Inc, Avid Radiopharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., Sirion Holdings, Inc., Aegerion Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.